InVivo Therapeutics to Present at Lazard Capital Markets 9th Annual Healthcare Conference
InVivo Therapeutics to Present at Lazard Capital Markets 9thAnnual Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today announced that CEO Frank Reynolds will present recent updates and meet one-on-one with potential investors during the Lazard Capital Markets 9th Annual Healthcare Conference November 13-14 at The Pierre Hotel in New York City.
Reynolds will present at 3:00pm ET on Wednesday, November 14; the presentation will be simultaneously webcast at http://wsw.com/webcast/lz13/nviv/. During his talk, Reynolds will provide an overview of InVivo's biomaterial technologies that are intended to provide structural support to a damaged spinal cord in order to spare tissue from scarring while improving recovery and prognosis after a traumatic spinal cord injury. The Company expects FDA approval in early 2013 to begin a clinical trial for the treatment in acute SCI.
Lazard Capital Markets provides research, sales and trading services and underwriting in the areas of equity, fixed income and convertible securities. Its proprietary events focus on alternative energy, medical technologies/healthcare, semiconductors, retail and apparel, providing a unique opportunity for emerging company leaders to present their business strategies and meet one-on-one with engaged investors to facilitate access to capital and mutual success. For more information or to register for the 9th Annual Healthcare Conference, visit www.lazardcap.com.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed from traumatic spinal cord injuries. The company was founded in 2005 based on proprietary technology co-invented by Robert S. Langer, ScD. Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital. In 2011, the company earned the prestigious 2011 David F. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.
Safe Harbor Statement
Certain statements contained in this press release that are not historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934, and the Company intends that such statements are subject to the safe harbor created thereby. These statements include, but are not limited to, those relating to the expected approval of the FDA to conduct human clinical trials for the Company's products, the expected commencement date of any approved human clinical trials, the expected size of the pilot study, the expectation that the scaffold product will be regulated under a HDE pathway, and the expected acceleration of commercialization of the Company's products resulting therefrom. These forward-looking statements are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to obtain FDA approval to conduct human clinical trials; whether the human clinical trials produce acceptable results; the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our Annual Report on Form 10-K for the year ended December 31, 2011 and subsequent filings with the SEC.
Forward-looking statements contained in this press release speak only as of the date of this release. Subsequent events or circumstances occurring after such date may render these statements incomplete or out of date. The Company undertakes no obligation and expressly disclaims any duty to update such statements.
InVivo Therapeutics Holdings Corp.
Lauren Mitarotondo, 617-863-5510
lmitarotondo@invivotherapeutics.com
KEYWORDS: United States North America Massachusetts
INDUSTRY KEYWORDS:
The article InVivo Therapeutics to Present at Lazard Capital Markets 9th Annual Healthcare Conference originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
